153 related articles for article (PubMed ID: 10875972)
21. Radiochemotherapy of malignant glioma in adults. Clinical experiences.
Kortmann RD; Jeremic B; Weller M; Plasswilm L; Bamberg M
Strahlenther Onkol; 2003 Apr; 179(4):219-32. PubMed ID: 12707711
[TBL] [Abstract][Full Text] [Related]
22. Regression of grade III astrocytoma during the treatment of CML with imatinib mesylate.
Jayawardena S; Sooriabalan D; Indulkar S; Kim HH; Matin A; Maini A
Am J Ther; 2006; 13(5):458-9. PubMed ID: 16988542
[TBL] [Abstract][Full Text] [Related]
23. MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes.
Jenkinson MD; Smith TS; Joyce K; Fildes D; du Plessis DG; Warnke PC; Walker C
Neurology; 2005 Jun; 64(12):2085-9. PubMed ID: 15985578
[TBL] [Abstract][Full Text] [Related]
24. Metabolic changes in cerebral gliomas within hours of treatment with intra-arterial BCNU demonstrated by phosphorus magnetic resonance spectroscopy.
Arnold DL; Shoubridge EA; Feindel W; Villemure JG
Can J Neurol Sci; 1987 Nov; 14(4):570-5. PubMed ID: 3690427
[TBL] [Abstract][Full Text] [Related]
25. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K
Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480
[TBL] [Abstract][Full Text] [Related]
26. [Chemotherapy in brain tumors].
van den Bent MJ; Schellens JH; Sillevis Smitt PA; Vecht CJ
Ned Tijdschr Geneeskd; 1996 Mar; 140(13):702-6. PubMed ID: 8668248
[No Abstract] [Full Text] [Related]
27. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.
Levin VA; Hess KR; Choucair A; Flynn PJ; Jaeckle KA; Kyritsis AP; Yung WK; Prados MD; Bruner JM; Ictech S; Gleason MJ; Kim HW
Clin Cancer Res; 2003 Mar; 9(3):981-90. PubMed ID: 12631596
[TBL] [Abstract][Full Text] [Related]
28. [Clinical significance of mustoforan in management of malignant glioma].
Kobiakov GL
Vopr Onkol; 2007; 53(6):724-9. PubMed ID: 18416147
[No Abstract] [Full Text] [Related]
29. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
30. Management of patients with low-grade gliomas.
Gilbert MR; Lang FF
Neurol Clin; 2007 Nov; 25(4):1073-88, ix. PubMed ID: 17964026
[TBL] [Abstract][Full Text] [Related]
31. Recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2) immunotherapy with ranimustine chemotherapy and concurrent radiation therapy for malignant astrocytomas.
Fukushima T; Yamamoto M; Oshiro S; Tsugu H; Hirakawa K; Soma G
Anticancer Res; 2003; 23(6a):4473-81. PubMed ID: 14666736
[TBL] [Abstract][Full Text] [Related]
32. Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma.
Gupta M; Djalilvand A; Brat DJ
Am J Clin Pathol; 2005 Nov; 124(5):755-68. PubMed ID: 16203285
[TBL] [Abstract][Full Text] [Related]
33. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
Fortin D; Desjardins A; Benko A; Niyonsega T; Boudrias M
Cancer; 2005 Jun; 103(12):2606-15. PubMed ID: 15880378
[TBL] [Abstract][Full Text] [Related]
34. [Histological classification of human gliomas: state of art and controversies].
Figarella-Branger D; Bouvier C
Bull Cancer; 2005 Apr; 92(4):301-9. PubMed ID: 15888386
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy for malignant brain tumors of astrocytic and oligodendroglial lineage.
Hofer S; Herrmann R
J Cancer Res Clin Oncol; 2001 Feb; 127(2):91-5. PubMed ID: 11216919
[TBL] [Abstract][Full Text] [Related]
36. [Results of clinical application of methods of individual selection of chemotherapeutic preparations in the treatment of gliomas].
Apshkalne DL; Kruminia GA; Kikut RP; Kotel'nikov VM
Zh Vopr Neirokhir Im N N Burdenko; 1980; (6):7-12. PubMed ID: 6258363
[TBL] [Abstract][Full Text] [Related]
37. Oligodendrogliomas.
Reiche W; Grunwald I; Hermann K; Deinzer M; Reith W
Acta Radiol; 2002 Sep; 43(5):474-82. PubMed ID: 12423457
[TBL] [Abstract][Full Text] [Related]
38. [Chemotherapy of cerebral gliomas. 1st results with intracarotid methotrexate infusions].
Luyendijk W; van Beusekom GT
Ned Tijdschr Geneeskd; 1965 Dec; 109(52):2490-7. PubMed ID: 5849922
[No Abstract] [Full Text] [Related]
39. [Chemotherapy for brain tumor].
Takahashi H; Tanaka R
Nihon Rinsho; 2005 Sep; 63 Suppl 9():452-5. PubMed ID: 16201563
[No Abstract] [Full Text] [Related]
40. OLIG2 as a specific marker of oligodendroglial tumour cells.
Marie Y; Sanson M; Mokhtari K; Leuraud P; Kujas M; Delattre JY; Poirier J; Zalc B; Hoang-Xuan K
Lancet; 2001 Jul; 358(9278):298-300. PubMed ID: 11498220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
